| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary molecular target is the 5-HT1A receptor, where buspirone acts as a partial agonist with high affinity (Ki approximately 10–20 nM); it also binds dopamine D2 autoreceptors as an antagonist (Ki approximately 20–30 nM) and has weak affinity for α1-adrenergic and 5-HT2 receptors, with the 5-HT1A partial agonism underlying its anxiolytic and antidepressant-augmenting effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, buspirone-d8 competes with [3H]8-OH-DPAT for recombinant 5-HT1A receptors and with [3H]spiperone for dopamine D2 receptors, acting as a partial agonist in 5-HT1A-mediated [35S]GTPγS binding and cAMP inhibition assays; the deuterated form retains receptor binding and functional activity while enabling mass spectrometric quantification. |
| ln Vivo |
In vivo, oral buspirone produces anxiolytic-like effects in rodent conflict and social interaction models and enhances antidepressant-like responses in forced swim and learned helplessness paradigms; it increases extracellular serotonin and dopamine in prefrontal cortex, and the deuterated form is used to quantify plasma and brain exposure and to assess 5-HT1A occupancy in pharmacokinetic/pharmacodynamic studies.
|
| Enzyme Assay |
Noncellular binding assays incubate membrane homogenates from cells expressing recombinant human 5-HT1A or dopamine D2 receptors with selective radioligands ([3H]8-OH-DPAT or [3H]spiperone) and increasing concentrations of buspirone-d8; nonspecific binding is defined with unlabeled 5-HT or haloperidol, and Ki values are calculated to quantify affinity and selectivity.
|
| Cell Assay |
Cellular functional assays use CHO or HEK293 cells expressing 5-HT1A receptors and measure agonist-stimulated [35S]GTPγS binding or inhibition of forskolin-stimulated cAMP accumulation; buspirone-d8 is tested for partial agonist efficacy relative to 5-HT, and dopamine D2 antagonist activity is assessed in cells expressing D2 receptors by inhibition of quinpirole-induced GTPγS binding.
|
| Animal Protocol |
Animal protocols administer buspirone-d8 orally or intraperitoneally to rats or mice at doses of 1–30 mg/kg; anxiolytic-like activity is measured in elevated plus maze, Vogel conflict, or social interaction tests, and brain and plasma concentrations are quantified by LC-MS/MS to relate 5-HT1A occupancy to behavioral effects, with microdialysis measuring extracellular serotonin and dopamine.
|
| References |
| Molecular Formula |
C21H31N5O2.HCL
|
|---|---|
| Molecular Weight |
421.96408
|
| Exact Mass |
393.298
|
| CAS # |
204395-49-3
|
| Related CAS # |
Buspirone;36505-84-7
|
| PubChem CID |
45038479
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
613.9±65.0 °C at 760 mmHg
|
| Melting Point |
198-200ºC
|
| Flash Point |
325.1±34.3 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
3.43
|
| tPSA |
69.64
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
529
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.C1C=NC(N2CCN(C(C(C(C(N3C(=O)CC4(CCCC4)CC3=O)([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])CC2)=NC=1
|
| InChi Key |
QWCRAEMEVRGPNT-QGZHXTQCSA-N
|
| InChi Code |
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2/i3D2,4D2,10D2,11D2
|
| Chemical Name |
8-[1,1,2,2,3,3,4,4-octadeuterio-4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3699 mL | 11.8495 mL | 23.6989 mL | |
| 5 mM | 0.4740 mL | 2.3699 mL | 4.7398 mL | |
| 10 mM | 0.2370 mL | 1.1849 mL | 2.3699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.